Síndrome antifosfolipídica

Autores

  • Ricard Cervera Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain
  • Gerard Espinosa Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain

DOI:

https://doi.org/10.24950/rspmi/revisao/4/2018

Palavras-chave:

Acidente Vascular Cerebral, Anticorpos Anticardiolipina, Anticorpos Antifosfolipídeos, Síndrome Antifosfolipídica

Resumo

A síndrome antifosfolipídica (SAF) carateriza-se pelo desenvolvimento de tromboses venosas e/ou arteriais, muitas vezes múltiplas, e pela morbidade gestacional (por perdas fetais recorrentes), na presença de anticorpos antifosfolipídicos. As estimativas indicam que a incidência da SAF é de cerca de 5 novos casos por 100 000 pessoas por ano e a prevalência é de cerca de 40-50 casos por 100 000 pessoas. Os aPL são positivos em aproximadamente 13% dos pacientes com acidente vascular cerebral, 11% com enfarte do miocárdio, 9,5% dos pacientes com trombose venosa profunda e 6% dos pacientes com morbidade gestacional. Atualmente, há consenso no tratamento de pacientes com SAF com trombose com anticoagulação oral de longa duração e para evitar manifestações obstétricas com o uso de aspirina e heparina. Esta revisão resume os principais conhecimentos sobre os aspectos clínicos e terapêuticos desta síndrome.

Downloads

Não há dados estatísticos.

Referências

Cervera R, Espinosa, Khamashta MA. Antiphospholipid syndrome in systemic autoimmune diseases. 2nd ed. Amsterdam: Elsevier; 2016.

Cervera R, Asherson RA, Acevedo ML, Gomez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. 2004;63:1312-7.

Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35:322-32.

Gómez-Puerta JA, Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine. 2005;84:225-30.

Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry.Autoimmun Rev. 2016;15:1120-4. doi: 10.1016/j.autrev.2016.09.010.

Durcan L, Petri M. Epidemiology of the Antiphospholipid Syndrome. In: Cervera R, Espinosa, Khamashta MA, editors. Antiphospholipid syndrome in systemic autoimmune diseases. 2nd ed. Amsterdam: Elsevier; 2016.p. 17-30.

Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.Arthritis Care Res. 2013; 65: 1869-73. doi: 10.1002/acr.22066.

Cervera R, Espinosa G, Bucciarelli S, Gomez-Puerta JA, Font J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev. 2006;6:81-4.

Cervera R, Bucciarelli S, Plasin MA, Gomez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009;32:240- 5. doi: 10.1016/j.jaut.2009.02.008.

Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol. 2010; 6: 296-300. doi: 10.1038/nrrheum.2010.47.

Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-44. doi: 10.1056/NEJMra1112830.

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheumatol. 2002;46:1019-27.

Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428-32. doi: 10.1136/ard.2008.093179.

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74: 1011-8. doi: 10.1136/annrheumdis-2013-204838.

Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res. 2010;62:302-7. doi: 10.1002/acr.20098.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013;52:1397-403. doi: 10.1093/rheumatology/kes388.

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 1999;42:1309-11.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295- 306.

Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66:927-30.

Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-4.

Cervera R, Font J, Gomez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-9.

Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 (in press). doi: 10.1111/jth.14192.

Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol. 2015;11:586-96. doi: 10.1038/nrrheum.2015.88.

Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. J Autoimmun. 2018;90:1-27. doi: 10.1016/j.jaut.2018.02.003.

Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007.

Grika EP, Ziakas PD, Zintzaras E, Moutsopoulos HM, Vlachoyiannopoulos PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39:516-23. doi: 10.3899/jrheum.110800.

Downloads

Publicado

01-04-2022

Como Citar

1.
Cervera R, Espinosa G. Síndrome antifosfolipídica. RPMI [Internet]. 1 de Abril de 2022 [citado 7 de Fevereiro de 2023];25(4):308-. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/546

Edição

Secção

Artigos de Revisão